SunnyVale, CA, April 21, 2020 – AlgoMedica, Inc. is pleased to announce its lead participation in a consortium of eight European institutions that have submitted a proposal to the European Union to help combat COVID-19. The consortium will integrate PixelShine™, the artificial intelligence (AI) powered software that AlgoMedica developed to improve the quality of ultralow dose computed tomography (ultra LDCT) imaging studies. The consortium is seeking €2M in funding from the EU to establish a standardized and quantitative procedure to enable improved and faster diagnosis of COVID using ultra low dose CT and medical imaging AI.
To ensure the lowest possible radiation dose, chest CT scans are performed with ultra LDCT. LDCT is beneficial to patients because several CT studies are required during the Covid-19 diagnosis and follow-up process. Ultra LDCT images have more noise than conventional (high dose) CT scans. The consortium will implement PixelShine to eliminate noise from the ultra LDCT studies, and ensure the best possible image quality. This is a critical step because image noise can mask pathology and make an accurate diagnosis more difficult. The images will then be analyzed by InferRead™ CT Pneumonia, a deep learning and AI based product from InferVision. All scans will be read by radiologists from the Bio-Medico di Roma (UCBM) in Italy, the Groningen University Hospital (UMCG) in the Netherlands and Heidelberg University Hospital (UKHD) in Germany.
While a normal CT scan of the chest exposes the body to the equivalent radiation dose to which a human is naturally exposed for a whole year in everyday life but with AlgoMedica’s PixelShine Software, "The radiation exposure can be reduced to ten percent without impacting the clinical utililty of the study," explains Mikael Strindlund, CEO of AlgoMedica.
Key benefits and goals:
1. Facilitate faster COVID diagnosis by using ultra-low dose CT chest imaging and AI image analysis.
2. Provide diagnostic quality ultra-low dose CT studies that can be evaluated by imaging AI analysis software.
3. Enable safe ultra-low dose followup imaging to COVID patients.
About PixelShine and AlgoMedica
PixelShine by Algomedica utilizes AI to improve the quality of any CT exam by reducing the inherent image noise. This is particularly applicable ultra-low dose CT scanning applications such as lung screening. By de-noising images using Deep Learning technology, Pixelshine empowers healthcare providers to acquire high-quality CT scans using substantially lower radiation. PixelShine is also vendor agnostic and can enhance the quality of noisy CT scans acquired by all types of CT scanners, including older and refurbished models. PixelShine processes noisy scans within a few minutes depending on the type of CT scan, requires no user interaction and can be remotely installed. Pixelshine can also extend the life of the Xray tube, resulting in capital savings and reduction of downtime and revenue loss. Learn more at www.algomedica.com
Back to HCB News
